Immunomedics (IMMU) 3.84 $IMMU
Immunomedics Has Bottomed, Will Likely Hurdle Its Most Significant Upcoming Catalyst
Clinically Sound Investor - at Seeking Alpha - Thu Feb 12, 3:28PM CST
IMMU: 3.84 (unch)
Immunomedics Announces Completion of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020
GlobeNewswire - Thu Feb 12, 8:00AM CST
Immunomedics, Inc., (Nasdaq:IMMU) announced today the closing of its previously announced offering of 4.75% Convertible Senior Notes due 2020 (the "Convertible Notes"
in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . Immunomedics issued $85 million aggregate principal amount of its Convertible Notes in an initial closing on February 11, 2015, and in addition, the initial purchasers notified Immunomedics that they have exercised, in full, the option granted to them by Immunomedics to purchase an additional $15 million aggregate principal amount of the Convertible Notes which is expected to close on February 17, 2015.
IMMU: 3.84 (unch)
Immunomedics prices debt offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:09AM CST
IMMU: 3.84 (unch)
Immunomedics Announces Pricing of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020
GlobeNewswire - Thu Feb 05, 6:22PM CST
Immunomedics, Inc., (Nasdaq:IMMU) announced today the pricing of its offering of $85,000,000 aggregate principal amount of 4.75% Convertible Senior Notes due 2020 (the "Convertible Notes" in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Immunomedics also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes. The offering of the Convertible Notes is expected to close on February 11, 2015, subject to customary closing conditions.
IMMU: 3.84 (unch)
Why Immunomedics Inc. Shares Crashed Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 05, 1:58PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Immunomedics shares fell by more than 15% today after...
IMMU: 3.84 (unch)
Immunomedics set for debt offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 12:26PM CST
IMMU: 3.84 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 11:45AM CST
IMMU: 3.84 (unch), AXGN: 3.45 (+0.02), CLW: 63.20 (-0.74), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HSNI: 67.32 (+1.52), LQDT: 9.52 (+0.09), EOX: 1.15 (unch), GLUU: 5.12 (+0.14), WSTL: 1.45 (+0.10), LFVN: 1.11 (-0.02), HSP: 87.35 (unch), GENE: 8.04 (+1.90), ADEP: 6.93 (-0.30), EARS: 5.88 (-0.01), IVC: 17.13 (+0.15), QUIK: 2.17 (+0.01), ENRJ: 2.81 (+0.06), FARM: 24.00 (-0.19), OSUR: 8.13 (+0.06)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Immunomedics reports 2Q loss
Automated Insights - Wed Feb 04, 5:24PM CST
MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Wednesday reported a loss of $11.4 million in its fiscal second quarter.
IMMU: 3.84 (unch)
Immunomedics Announces Proposed Offering of $85 Million of Convertible Senior Notes Due 2020
GlobeNewswire - Wed Feb 04, 4:52PM CST
Immunomedics, Inc., (Nasdaq:IMMU) announced today that it intends to offer, subject to market conditions and other considerations, $85,000,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Convertible Notes" in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Immunomedics also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes.
IMMU: 3.84 (unch)
Immunomedics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 3:47PM CST
IMMU: 3.84 (unch)
Immunomedics Announces Second Quarter Fiscal 2015 Results and Clinical Program Developments
GlobeNewswire - Wed Feb 04, 3:15PM CST
Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the second quarter ended December 31, 2014. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
IMMU: 3.84 (unch)
Immunomedics Announces Conference Call and Webcast for Second Quarter Fiscal 2015 Financial Results
GlobeNewswire - Tue Feb 03, 3:37PM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, February 5, 2015 at 10:00 a.m. Eastern Time to discuss financial results for the second quarter of fiscal year 2015, and review key clinical developments and future planned activities.
IMMU: 3.84 (unch)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Immunomedics Has Returned 31.7% Since SmarTrend Recommendation (IMMU)
Comtex SmarTrend(R) - Thu Jan 29, 5:00PM CST
SmarTrend identified an Uptrend for Immunomedics (NASDAQ:IMMU) on October 30th, 2014 at $4.01. In approximately 3 months, Immunomedics has returned 31.67% as of today's recent price of $5.28.
IMMU: 3.84 (unch)
Immunomedics Announces Dismissal of Putative Class Action Lawsuit
GlobeNewswire - Thu Jan 29, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the United States District Court for the District of New Jersey in a putative class action lawsuit, styled Nasyrova v. Immunomedics, Inc., has granted the Company's motion to dismiss the complaint in its entirety.
IMMU: 3.84 (unch)
Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 3.84 (unch), PFE: 34.64 (-0.23), BIOD: 1.38 (-0.14)
Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers
GlobeNewswire - Tue Jan 20, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), produces partial response (PR) in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated. Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression (TTP) exceeding that of last prior therapy in many cases. Response and TTP were evaluated by computed tomography (CT) based on RECIST criteria.
IMMU: 3.84 (unch)
Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:50PM CST
Immunomedics, Inc.'s (IMMU) sacituzumab govitecan has received fast track status from the FDA for triple-negative breast cancer.
IMMU: 3.84 (unch), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), RGDO: 1.17 (+0.02)
Stock to Watch: Immunomedics Down 6.2% (IMMU)
Comtex SmarTrend(R) - Tue Jan 06, 12:40PM CST
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 6.2% to $4.68 on 1.1x average daily volume. Immunomedics has traded 767,000 shares thus far today, vs. average volume of 691,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -1.2%) and underperformed the S&P 500 (-6.2% to the S&P's -1.2%) during today's trading.
IMMU: 3.84 (unch)
Immunomedics Has Bottomed, Will Likely Hurdle Its Most Significant Upcoming Catalyst
Clinically Sound Investor - at Seeking Alpha - Thu Feb 12, 3:28PM CST
IMMU: 3.84 (unch)
Immunomedics Announces Completion of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020
GlobeNewswire - Thu Feb 12, 8:00AM CST
Immunomedics, Inc., (Nasdaq:IMMU) announced today the closing of its previously announced offering of 4.75% Convertible Senior Notes due 2020 (the "Convertible Notes"
in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . Immunomedics issued $85 million aggregate principal amount of its Convertible Notes in an initial closing on February 11, 2015, and in addition, the initial purchasers notified Immunomedics that they have exercised, in full, the option granted to them by Immunomedics to purchase an additional $15 million aggregate principal amount of the Convertible Notes which is expected to close on February 17, 2015. IMMU: 3.84 (unch)
Immunomedics prices debt offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:09AM CST
IMMU: 3.84 (unch)
Immunomedics Announces Pricing of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020
GlobeNewswire - Thu Feb 05, 6:22PM CST
Immunomedics, Inc., (Nasdaq:IMMU) announced today the pricing of its offering of $85,000,000 aggregate principal amount of 4.75% Convertible Senior Notes due 2020 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Immunomedics also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes. The offering of the Convertible Notes is expected to close on February 11, 2015, subject to customary closing conditions. IMMU: 3.84 (unch)
Why Immunomedics Inc. Shares Crashed Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 05, 1:58PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Immunomedics shares fell by more than 15% today after...
IMMU: 3.84 (unch)
Immunomedics set for debt offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 12:26PM CST
IMMU: 3.84 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 11:45AM CST
IMMU: 3.84 (unch), AXGN: 3.45 (+0.02), CLW: 63.20 (-0.74), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HSNI: 67.32 (+1.52), LQDT: 9.52 (+0.09), EOX: 1.15 (unch), GLUU: 5.12 (+0.14), WSTL: 1.45 (+0.10), LFVN: 1.11 (-0.02), HSP: 87.35 (unch), GENE: 8.04 (+1.90), ADEP: 6.93 (-0.30), EARS: 5.88 (-0.01), IVC: 17.13 (+0.15), QUIK: 2.17 (+0.01), ENRJ: 2.81 (+0.06), FARM: 24.00 (-0.19), OSUR: 8.13 (+0.06)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Immunomedics reports 2Q loss
Automated Insights - Wed Feb 04, 5:24PM CST
MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Wednesday reported a loss of $11.4 million in its fiscal second quarter.
IMMU: 3.84 (unch)
Immunomedics Announces Proposed Offering of $85 Million of Convertible Senior Notes Due 2020
GlobeNewswire - Wed Feb 04, 4:52PM CST
Immunomedics, Inc., (Nasdaq:IMMU) announced today that it intends to offer, subject to market conditions and other considerations, $85,000,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Immunomedics also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes. IMMU: 3.84 (unch)
Immunomedics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 3:47PM CST
IMMU: 3.84 (unch)
Immunomedics Announces Second Quarter Fiscal 2015 Results and Clinical Program Developments
GlobeNewswire - Wed Feb 04, 3:15PM CST
Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the second quarter ended December 31, 2014. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
IMMU: 3.84 (unch)
Immunomedics Announces Conference Call and Webcast for Second Quarter Fiscal 2015 Financial Results
GlobeNewswire - Tue Feb 03, 3:37PM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, February 5, 2015 at 10:00 a.m. Eastern Time to discuss financial results for the second quarter of fiscal year 2015, and review key clinical developments and future planned activities.
IMMU: 3.84 (unch)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Immunomedics Has Returned 31.7% Since SmarTrend Recommendation (IMMU)
Comtex SmarTrend(R) - Thu Jan 29, 5:00PM CST
SmarTrend identified an Uptrend for Immunomedics (NASDAQ:IMMU) on October 30th, 2014 at $4.01. In approximately 3 months, Immunomedics has returned 31.67% as of today's recent price of $5.28.
IMMU: 3.84 (unch)
Immunomedics Announces Dismissal of Putative Class Action Lawsuit
GlobeNewswire - Thu Jan 29, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the United States District Court for the District of New Jersey in a putative class action lawsuit, styled Nasyrova v. Immunomedics, Inc., has granted the Company's motion to dismiss the complaint in its entirety.
IMMU: 3.84 (unch)
Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 3.84 (unch), PFE: 34.64 (-0.23), BIOD: 1.38 (-0.14)
Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers
GlobeNewswire - Tue Jan 20, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), produces partial response (PR) in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated. Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression (TTP) exceeding that of last prior therapy in many cases. Response and TTP were evaluated by computed tomography (CT) based on RECIST criteria.
IMMU: 3.84 (unch)
Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:50PM CST
Immunomedics, Inc.'s (IMMU) sacituzumab govitecan has received fast track status from the FDA for triple-negative breast cancer.
IMMU: 3.84 (unch), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), RGDO: 1.17 (+0.02)
Stock to Watch: Immunomedics Down 6.2% (IMMU)
Comtex SmarTrend(R) - Tue Jan 06, 12:40PM CST
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 6.2% to $4.68 on 1.1x average daily volume. Immunomedics has traded 767,000 shares thus far today, vs. average volume of 691,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -1.2%) and underperformed the S&P 500 (-6.2% to the S&P's -1.2%) during today's trading.
IMMU: 3.84 (unch)
